Business Times Article: How Singapore can Lead Biopharma Innovation by INTERPAT & SAPI

INTERPAT supported SAPI (Singapore Association of Pharmaceutical Industries) and contributed to an IP article which highlights the importance of safeguarding Singapore’s attractiveness as a biopharmaceutical innovation hub through strong IP protection.

Full Text can be found in our resources by clicking on the following link: Business Times Article and full text.




The Singapore Association of Pharmaceutical Industries (SAPI) aims to make innovative medicine accessible to patients in Singapore. We achieve this through a sustainable and valued partnership with healthcare professionals and providers, government and patient group stakeholders, and a reputation of consistent ethical behaviour.

for more information, visit their website at the following link: SAPI website